AngioDynamics (NSDQ:ANGO) said yesterday it enrolled the 1st patient in a new database analysis of patients treated with its AngioVac system.
The Rapid database will evaluate patterns of use, safety and effectiveness data for patients treated with the AngioVac system to remove fresh, soft thrombi or emboli, the Albany, N.Y.-based company said.
“So far, we have centers in 31 states that want to take part in the registry. Our goal is to include as many potential collaborators as possible, and start gathering much needed data regarding procedural and patient outcomes,” principal investigator Dr. John Moriarty said in a press release.
The goal of the study is to capture functional short-term clinical data for patients treated with the AngioVac and analyze that data to possibly develop and refine standards of care with the device, the company said.
“AngioVac continues to impress clinically as the second-generation of the device, cleared for use earlier this year by the U.S. Food and Drug Administration and released to the market in April, is driving broader interest among clinician. AngioDynamics is a pioneer when it comes to the minimally invasive en bloc removal of fresh, soft thrombi or emboli. We feel we have a responsibility to work with our physician partners to gather patient data and continue improving our procedures, products and patient outcomes. We are excited to launch this initiative and look forward to the collaboration which in the end will benefit patients,” global franchise leader and senior veep Chris Crisman said in prepared remarks.
